Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K. Paik, Xiuning Le, Josef Straub et al.|New England Journal of Medicine|2020Cited by 879
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort BXiuning Le, Paul K. Paik, Luis Paz‐Ares et al.|Cell Reports Medicine|2023Cited by 18
Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level <i>MET</i> amplification (<i>MET</i>amp) detected by liquid biopsy (LBx).Xiuning Le, Paul K. Paik, Luis Paz‐Ares et al.|Journal of Clinical Oncology|2022Cited by 13
Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of TepotinibChristian Rolfo, Paul K. Paik, Aurora O’Brate et al.|Clinical Cancer Research|2025Cited by 4
1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinibChristian Rolfo, Paul K. Paik, A.M. OBrate Grupp et al.|Annals of Oncology|2023Cited by 4